Hypersensitivity reactions to folinic acid: mechanisms involved based on two case reports and a literature review

• Case Report
• Open Access

• Matveï Apraxine, 
• Marc Van den Eynde, 
• Astrid De Cuyper & 
• Françoise Pirson 

Allergy, Asthma & Clinical Immunology volume 18, Article number: 107 (2022) 

• details

Abstract

Background

Hypersensitivity reactions (HSR) to antineoplastic agents are an increasing problem, especially when they lead to treatment discontinuation, sometimes without any equivalent therapeutic option. HSR to folinic acid (FA), used particularly for the treatment of digestive carcinoma along with oxaliplatin and 5-fluorouracil, are rare. Only seven publications report HSR to FA, mainly confirmed by the disappearance of symptoms after the withdrawal of FA from chemotherapy. Only two papers describe allergy testing. Due to the difficult diagnosis, patients usually receive several further cycles of chemotherapy with progressively more intense symptoms before the withdrawal of FA.

Topical cyclosporine versus allergen specific immunotherapy in perennial allergic conjunctivitis

 

Int Ophthalmol. 2022 Dec 14 : 1–9.

doi: 10.1007/s10792-022-02612-y [Epub ahead of print]

Ceylan Uslu Dogan,1 Can Tuzer,2 Ibrahim Cagri Turker,1 Abdurrahman Alpaslan Alkan,3 Damla Culha,4 and Semra Demir2

Abstract

Purpose

Symptom control in the long-term with less side effects is important in perennial allergic conjunctivitis, since would improve quality of life. This study aimed to assess the clinical efficacies of topical cyclosporin A and subcutaneous allergen immunotherapy (SCIT) in terms of sign control in perennial allergic conjunctivitis.

Which non-steroidal anti-inflammatory drug (NSAID) is safer in patients with Non-steroids Exacerbated Respiratory Disease (N-ERD)? A single-center retrospective study

Tuberk Toraks. 2022 Dec;70(4):365-374. doi: 10.5578/tt.20229608.

Mehmet Erdem Çakmak

Free article

Abstract

Introduction: In patients with NSAID-Exacerbated Respiratory Disease (N-ERD), respiratory symptoms occur as a result of the use of cyclooxygenase (COX)-1 inhibitor non-steroidal anti-inflammatory drugs (NSAIDs). Patients with N-ERD generally tolerate selective COX-2 inhibitor NSAIDs. However, respiratory symptoms may be exacerbated in patients with N-ERD due to the intake of selective COX-2 inhibitor NSAIDs. The aim of this study was to evaluate which selective or partial COX-2 inhibitor NSAID is safer in patients with N-ERD.

Nationwide survey of refractory asthma with bronchiectasis by inflammatory subtypes

• Research
• Open Access
• 
  

• Natsuko Nomura, 
• Hisako Matsumoto, 
• Akihito Yokoyama, 
• Yoshihiro Nishimura, 
• Koichiro Asano, 
• Akio Niimi, 
• Yuji Tohda, 
• Norihiro Harada, 
• Hiroyuki Nagase, 
• Makoto Nagata, 
• Hiromasa Inoue, 
• Mitsuko Kondo, 
• Takahiko Horiguchi, 
• Nobuaki Miyahara, 
• Nobuyuki Hizawa, 
• Masayuki Hojo, 
• Noboru Hattori, 
• Naozumi Hashimoto, 
• Akira Yamasaki, 
• Toru Kadowaki, 
• Tomoki Kimura, 
• Mari Miki, 
• Hirokazu Taniguchi, 
• Mikio Toyoshima, 
• Tetsuji Kawamura, 
• Osamu Matsuno, 
• Yoko Sato, 
• Hironobu Sunadome, 
• Tadao Nagasaki, 
• Tsuyoshi Oguma, 
• Toyohiro Hirai on behalf of 
• the BEXAS study

Respiratory Research volume 23, Article number: 365 (2022) 

• details

Abstract

Rationale

Bronchiectasis and bronchiolitis are differential diagnoses of asthma; moreover, they are factors associated with worse asthma control.

Objective

We determined clinical courses of bronchiectasis/bronchiolitis-complicated asthma by inflammatory subtypes as well as factors affecting them.

Treatment of Allergic Rhinitis and Asthma in Primary Care: Dispensations Do Not Align with Prescriptions

J Asthma Allergy. 2022 Nov 25;15:1721-1729. doi: 10.2147/JAA.S376786. eCollection 2022.

Manon Belhassen 1, Marjorie Bérard 1, Gilles Devouassoux 2, Faustine Dalon 1, Jean Bousquet 3 4, Eric Van Ganse 1 2 5 

Free PMC article

Abstract

Background: Appropriate use of effective treatments is required for satisfactory control of allergic symptoms. Coherent medical care -regular prescribing by the same Health Care Professionals- is a preliminary need.

Objective: We investigated the numbers of distinct prescribers, the regularity of medical visits, and the agreement between prescriptions and associated dispensations in individual patients with perennial allergic rhinitis (PAR) and asthma.

Methods: In primary care electronic health records (EHRs), a cohort of patients with PAR and asthma was identified. Individual EHRs were linked to corresponding claims recording all dispensations. Prescribing patterns were analyzed for the major treatment classes, and the dispensations linked to individual prescriptions were retrieved to compute the proportions of days covered (PDCs) for asthma and PAR therapy.

Diversity of malignancies in patients with different types of inborn errors of immunity

Research Open Access

• Marzieh Tavakol, 
• Samaneh Delavari, 
• Fereshte Salami, 
• Sarina Ansari, 
• Seyed Erfan Rasouli, 
• Zahra Chavoshzadeh, 
• Roya Sherkat, 
• Hamid Ahanchian, 
• Soheila Aleyasin, 
• Hossein Esmaeilzadeh, 
• Nasrin Moazzen, 
• Alireza Shafiei, 
• Farhad Abolnezhadian, 
• Sara Iranparast, 
• Sareh sadat Ebrahimi, 
• Tannaz Moeini Shad, 
• Salar Pashangzadeh, 
• Farzad Nazari, 
• Arezou Rezaei, 
• Ali Saeedi-Boroujeni, 
• Mohammad Nabavi, 
• Saba Arshi, 
• Morteza Fallahpour, 
• Mohammad hassan Bemanian, 
• …
• Nima Rezaei 

Allergy, Asthma & Clinical Immunology volume 18, Article number: 106 (2022) 

Abstract

Genetic defects in the development, maturation, and/or function of the immune cells can lead to Inborn errors of immunity (IEI) which may predispose patients to malignancies. The overall risk for cancer in children with IEI ranges from 4 to 25% and the type of malignancy is highly dependent on the specific mutant gene underlying IEI. We investigated 3056 IEI patients registered in the Iranian national registry between the years 1999 and 2020 in this retrospective cohort study. The frequency of malignancy and its association with the type of IEI in these patients were evaluated.

International recommendations on epinephrine auto-injector doses often differ from standard weight-based guidance: a review and clinical proposals

• Review
• Open Access
• 
  

• Sten Dreborg, 
• Graham Walter & 
• Harold Kim 

Allergy, Asthma & Clinical Immunology volume 18, Article number: 102 (2022) 

• details

Abstract

Background

In anaphylaxis, the dosing of injectable epinephrine in medical settings has been arbitrarily recommended to be 0.01 mg/kg of body weight. For ethical reasons, there have been no dose–response studies or double-blind studies performed on patients with active anaphylaxis. Intramuscular delivery of epinephrine has been the standard. Auto-injectors for use in the treatment of anaphylaxis are available in four strengths (0.1, 0.15, 0.3, and 0.5 mg). However, in many countries, only the 0.15 and 0.3 mg strengths are available. Consequently, many adult, heavy patients are prescribed the 0.3 mg dose, which may result in only one-fifth to one-third of the recommended weight-based dose being administered in heavy patients experiencing anaphylaxis. Underdosing may have therefore contributed to mortality in anaphylaxis.

Associations between food allergy, country of residence, and healthcare access

• Letter to the Editor
• Open Access
• 
  

• Kaitlyn A. Merrill, 
• Elissa M. Abrams, 
• Sara V. Good, 
• Ruchi S. Gupta, 
• Carina Venter, 
• Tara Lynn M. Frykas, 
• Michael A. Golding & 
• Jennifer L. P. Protudjer 

Allergy, Asthma & Clinical Immunology volume 18, Article number: 103 (2022) 

• details

Abstract

Background

To date, little consideration has been given to access to allergy-related care, despite the fact that food allergy affects a considerable proportion of children. As such, the current study aimed to describe access to food allergy-related services in Canada and the United States (US).

Methods

Participants were recruited via social media from March-July 2021 and were asked to complete an online survey focused on food allergy-related medical care. Participants were Canadian and US residents who live with a child < 18 years old, with ≥ 1 food allergy. A series of logistic regressions were used to assess the associations between country of residence and type of allergy testing utilized during diagnosis.